Pharmaceutical Startup Sollievo Raising Capital via Equity Crowdfunding for New Drug Launch

Sollievo equity crowdfunding

Flagship drug Proviza(R) targets increasing safety for first responders and healthcare staff in crisis situations.

San Juan Capistrano, California Oct 27, 2022 (Issuewire.com) – Sollievo Pharmaceuticals seeks to improve the safety of healthcare providers with its first product, Proviza. Proviza is a fast-acting injectable sedative in development to address the rising incidence of injuries and abuse to healthcare staff when treating agitated and aggressive patients.

Nearly 50% of emergency physicians say they’ve been assaulted. 70% of emergency nurses reported being attacked on the job. The reasons for rising violence are numerous — mental health issues, drug abuse, understaffed emergency departments — but multiple experts emphasize the increase in emergency room patients. Such visits rose from 94.7 million in 1995 to 142.6 million in 2016, the American Hospital Association reports, and nearly half of U.S. hospital-associated medical care is delivered by emergency departments.

Sollievo CEO Robert Schultz, Ph.D., sees his company’s development of Proviza as a feasible front-line solution. That’s because Proviza is designed to be one of the fastest and most consistent sedatives of its kind. The benefits of such an approach are clear; patients suffering mental disturbances, including drug-induced violence, can quickly be rendered harmless before hurting anybody.

However, it’s not just about the violent patient. Doctors express concern that disruption of the ED/ER harms other patients and increases wait times for others. Proviza aims to reduce the time the staff is involved in treating these patients – which benefits everyone seeking emergency treatment.

To invest or learn more about the offering visit https://bit.ly/3eO226N

The Sollievo corporate website – http://sollievopharm.com/

About Sollievo

Sollievo produces solutions to unmet medical needs by modifying existing drugs or formulations. Proviza(R), their first product, will uniquely address the skyrocketing injury rates among doctors and nurses when treating acutely agitated and violent patients.

Sollievo founder & CEO Robert K Schultz, Ph.D., has over 40 years of experience in the pharmaceutical and medical device industries. Dr. Schultz previously served as President and Chief Operating Officer of REVA Medical, Inc., a San Diego-based medical device company.

Sollievo equity crowdfundingSollievo equity crowdfunding

Media Contact

Howard Sherman

howard@crowdfundbuzz.com

833-CROWDPR

http://www.crowdfundbuzz.com

Source :Sollievo Pharmaceuticals, Inc.

This article was originally published by IssueWire. Read the original article here.


comtex tracking

COMTEX_417499434/2777/2022-10-27T06:17:09

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Feature Georgia Heralds was involved in the writing and production of this article.